[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5894 Introduced in House (IH)]

<DOC>






116th CONGRESS
  2d Session
                                H. R. 5894

To direct the Secretary of Health and Human Services to issue guidance 
requiring the list prices of drugs to be included in advertisements for 
                              such drugs.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                           February 13, 2020

  Ms. Davids of Kansas (for herself, Ms. Slotkin, and Ms. Finkenauer) 
 introduced the following bill; which was referred to the Committee on 
                          Energy and Commerce

_______________________________________________________________________

                                 A BILL


 
To direct the Secretary of Health and Human Services to issue guidance 
requiring the list prices of drugs to be included in advertisements for 
                              such drugs.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Transparency in Prescription Drug 
Advertising Act''.

SEC. 2. PRICING TRANSPARENCY IN DRUG ADVERTISING.

    (a) In General.--Not later than one year after the date of 
enactment of this Act, the Secretary of Health and Human Services, in 
consultation with the Commissioner of Food and Drugs and the 
Administrator of the Centers for Medicare & Medicaid Services, shall 
issue department-wide guidance requiring the list prices of drugs to be 
included, as appropriate, in all advertising of drugs, including by 
means of television, newspapers, the internet, or other media.
    (b) Enforcement; Consistency.--The guidance under subsection (a)--
            (1) shall include appropriate enforcement mechanisms for 
        failure to make disclosures in accordance with the guidance; 
        and
            (2) should be consistent with the regulation of the Centers 
        for Medicare & Medicaid Services related to drug pricing 
        transparency.
                                 <all>